Skip to main content
Clinical Trials/NCT07617376
NCT07617376RecruitingPhase 4

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

Wroclaw Medical University1 site in 1 country400 target enrollmentStarted: November 12, 2025Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
400
Locations
1

Study Overview

Brief Summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.

In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Acute cardiac hospitalization,
  • Planned discharge home within the next 48 hours following completion of in-hospital treatment,
  • No prior influenza vaccination for the current influenza season.

Exclusion Criteria

  • History of a severe adverse reaction to influenza vaccination,
  • Allergy to any component of the vaccine to be administered,
  • Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,
  • Antibiotic therapy to be continued after discharge.

Investigators

Sponsor
Wroclaw Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Michał Tkaczyszyn, MD

Dr

Wroclaw Medical University

Study Sites (1)

Loading locations...

Similar Trials